tradingkey.logo
搜索

Telomir Pharmaceuticals Inc

TELO
添加自选
1.270USD
-0.030-2.31%
收盘 07/02, 13:00美东报价延迟15分钟
43.66M总市值
亏损市盈率 TTM

关于 Telomir Pharmaceuticals Inc 公司

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc简介

公司代码TELO
公司名称Telomir Pharmaceuticals Inc
上市日期Feb 09, 2024
CEOAminov (Erez)
员工数量- -
证券类型Ordinary Share
年结日Feb 09
公司地址900 West Platt Street, Suite 200
城市TAMPA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33606
电话18138642562
网址https://telomirpharma.com/
公司代码TELO
上市日期Feb 09, 2024
CEOAminov (Erez)

Telomir Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

常见问题

Telomir Pharmaceuticals Inc的前五大股东是谁?

Telomir Pharmaceuticals Inc 的前五大股东如下:Mr. Erez Aminov

有多少机构持有Telomir Pharmaceuticals Inc(TELO)的股份?

截至2026Q1,共有110家机构持有Telomir Pharmaceuticals Inc的股份,合计持有的股份价值约为3.42M,占公司总股份的9.95%。与2025Q4相比,机构持股有所增加,增幅为488600.00。